



www.shd.org.rs

J. Serb. Chem. Soc. 73 (6) 619–630 (2008)

JSCS–3744

Journal of
the Serbian
Chemical Society

JSCS@tmf.bg.ac.yu • www.shd.org.rs/JSCS

UDC 546.962+542.913:576+615.9

Original scientific paper

Synthesis, structural characterization and cytotoxic activity of two new organoruthenium(II) complexes

SANJA GRGURIĆ-ŠIPKA^{1*}, MOHAMED AL.ARBI M. ALSHTEWI¹, DEJAN JEREMIĆ^{1#},
GORAN N. KALUĐEROVIĆ², SANTIAGO GÓMEZ-RUIZ³, ŽELJKO ŽIŽAK⁴,
ZORICA JURANIĆ⁴ and TIBOR J. SABO¹

¹Faculty of Chemistry, University of Belgrade, Studentski trg 12–16, 11000 Belgrade,

²Department of Chemistry, Institute of Chemistry, Technology and Metallurgy,

Njegoševa 12, 11000 Belgrade, Serbia, ³Departamento de Química Inorgánica y

Analítica, E. S. C. E. T., Universidad Rey Juan Carlos, 28933 Móstoles, Madrid,

Spain and ⁴Institute of Oncology and Radiology, 11000 Belgrade, Serbia

(Received 27 December 2007, revised 4 March 2008)

Abstract: Two new *p*-cymene ruthenium(II) complexes containing as additional ligands *N*-methylpiperazine ($[(\eta^6\text{-}p\text{-cymene})\text{RuCl}_2(\text{CH}_3\text{NH}(\text{CH}_2)_4\text{NH})]\text{PF}_6$, complex **1**) or vitamin K₃-thiosemicarbazone ($[(\eta^6\text{-}p\text{-cymene})\text{RuCl}_2(\text{K}_3\text{tsc})]$, complex **2**) were synthesized starting from $[(\eta^6\text{-}p\text{-cymene})_2\text{RuCl}_2]_2$ and the corresponding ligand. The complexes were characterized by elemental analysis, IR, electronic absorption and NMR spectroscopy. The X-ray crystal structure determination of complex **1** revealed “piano-stool” geometry. The differences in the cytotoxic activity of the two complexes are discussed in terms of the ligand present.

Keywords: ruthenium(II) complexes; *p*-cymene; K₃-thiosemicarbazone; *N*-methylpiperazine; cytotoxic activity.

INTRODUCTION

The field of organoruthenium complexes has been widely explored in recent years with regard to biological activity as well as catalytic activity of these complexes.^{1–5} Many of these compounds are soluble in water and display cytotoxicity to cancer cells, including cisplatin-resistant cancer cells.^{6,7}

Vitamin K₃, menadione, (2-methylnaphthalene-1,4-dione), is a fat-soluble vitamin and it is necessary for the production of prothrombin and five other blood clotting factors in humans. It also regulates bone calcification.⁸ In addition, it was found that vitamin K₃, as well as its water-soluble derivative, menadione sodium bisulfite, has significant antitumor activity *in vitro* and *in vivo*.⁹

* Corresponding author. E-mail: sanjag@chem.bg.ac.yu

Serbian Chemical Society member.

doi: 10.2298/JSC0806619G

On the other hand, thiosemicarbazones play an important role in research related to biological activity.¹⁰ These ligands form complexes with metals and the influence of chelation on antitumor activity has been very intensively investigated.^{11,12} Thiosemicarbazones are the ligands of choice because thiosemicarbazones themselves exhibit antineoplastic activity. One of the most effective thiosemicarbazone is triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone).^{13,14} This compound acts as a very strong iron chelator and, consequently, inhibits ribonucleotide reductase (RR) activity.¹⁵ The role of RR in the rate of replication of cancer cells has been well established.¹⁶

Hitherto, the thiosemicarbazone derivative of vitamin K₃ was used in the preparation of complexes with metals, such as Mn(II), Co(II), Ni(II), Cu(II), Zn(II) and Au(I).^{17–19} It should be mentioned that the ruthenium chemistry of thiosemicarbazones has received little attention, especially concerning their potential antitumor activity. Ru(II) formed several complexes with thiosemicarbazones and some of them showed cytotoxic activity.^{20–22} In addition, recently a lot of other ruthenium complexes containing the arene moiety have been synthesized and some of them have been evaluated for activity both *in vitro* and *in vivo*.^{23–26} Some of the prepared complexes of the type $[(\eta^6\text{-arene})\text{-RuCl}(\text{X})(\text{Y})]$ showed cytotoxic activity to cisplatin-resistant cell lines. Preliminary structure–activity data showed that the hydrophobic arene group, the diamine NH group and the Cl leaving group may all play important roles in the anticancer activity of these complexes.²⁷

In this paper, the characterization of two newly synthesized complexes of Ru(II) with *p*-cymene, which contain additional ligands K₃tsc or *N*-methylpiperazine, is described.

EXPERIMENTAL

Materials

Menadione sodium bisulfite (MSB), thiosemicarbazide, α -terpinene and *N*-methylpiperazine were commercially available and used without further purification. MSB thiosemicarbazone (NaK₃tsc) was prepared by treating thiosemicarbazide with menadione sodium bisulfite in an ethanol–water mixture using a published procedure.¹⁷

The complex $[(\eta^6\text{-}p\text{-cymene})_2\text{RuCl}_2]_2$ was prepared following a published protocol.²⁸

Synthesis of the complexes

Synthesis of $[(\eta^6\text{-}p\text{-cymene})\text{RuCl}_2(\text{CH}_3\text{NH}(\text{CH}_2)_4\text{NH})]\text{PF}_6$ (1). A solution of *N*-methylpiperazine (0.07 ml, 0.50 mmol) in dry methanol (5.0 ml) was added to a solution of $[(\eta^6\text{-}p\text{-cymene})_2\text{RuCl}_2]_2$ (120 mg, 0.20 mmol) in dry methanol (10 ml). The resulting mixture was stirred 2 h in dark. Orange solution was then concentrated to half volume and 250 mg (1.5 mmol) of NH₄PF₆ was added. The light orange product that appeared during night was filtered off, washed with ethanol, and ether. Yield: 92.2 mg (42 %).

Synthesis of $[(\eta^6\text{-}p\text{-cymene})\text{RuCl}_2(\text{K}_3\text{tsc})]$ (2). A solution of K₃tsc (220 mg, 0.50 mmol) in dry methanol (5.0 ml) was added to a solution of $[(\eta^6\text{-}p\text{-cymene})_2\text{RuCl}_2]_2$ (120 mg, 0.20 mmol) in dry methanol (10 ml). The resulting mixture was stirred for 3 h. The obtained

orange solution was then concentrated to half volume and left at 4 °C overnight. The light orange product was filtered off, washed with methanol and then diethyl ether. Yield: 166 mg (67 %).

Physical measurements

Elemental analyses were carried out with an Elemental Vario EL III microanalyser. The infrared spectra were recorded on a Perkin–Elmer FTIR 31725X spectrometer using KBr pellets (4000–400 cm^{−1}). The electronic spectra were obtained using a GBC UV/Vis Cintra 40 spectrophotometer. The NMR spectra were recorded on a Varian Gemini 200 instrument. The chemical shifts for the ¹H and ¹³C spectra are referenced to the residual ¹H and ¹³C present in deuterated dimethyl sulfoxide.

X-ray crystal structure determination

A crystal of complex **1** suitable for an X-ray diffraction study was obtained by the slow diffusion of *n*-propanol into an aqueous solution of the complex. The data of complex **1** were collected with a CCD Oxford Xcalibur S ($\lambda(\text{MoK}\alpha) = 0.71073 \text{ \AA}$) using the ω and ϕ scan modes at 130 K. Semi-empirical correction for absorption was performed with SCALE3 ABSPACK.²⁹ The structure was solved by direct methods.³⁰ Structure refinement was performed with SHELXL-97.³¹ All non-hydrogen atoms were refined anisotropically and the H atoms were located in ΔF and refined isotropically. Table I lists crystallographic details. The hydrogen atoms from the *N*-methylpiperazine ligand were placed at their calculated positions and refined using the riding model. The PF₆[−] anions are disordered as demonstrated by their larger-than-normal mean-square displacement parameters. The structural disorder of the PF₆[−] anions explains the relatively high *R* factors. A disordered model for PF₆ with split F-atom positions was introduced. The resultant thermal parameters were better than those without the split of the F-atom positions. Also, the split of the F-atom positions in three parts were examined. In addition, the latter refinement involved severe correlations and the resultant thermal parameters of the F-atoms were still unreasonable. Therefore, the split positions within the PF₆[−] anion were introduced into the calculations and a least-squares refinement in the space group *P2*₁/*c* with disordered F-atoms was preferred with the present data.

TABLE I. Crystal data, data collection and refinement parameters for **1**

Empirical formula	C ₁₅ H ₂₇ Cl ₂ N ₂ RuF ₆ P
Formula weight, g mol ^{−1}	552.33
Crystal system/space group	monoclinic/ <i>P2</i> ₁ / <i>c</i>
<i>a</i> / Å	12.2534(7)
<i>b</i> / Å	7.9458(16)
<i>c</i> / Å	14.0359(8)
β / °	111.114(6)
<i>V</i> / Å ³	2082.2(2)
<i>Z</i>	4
ρ / g cm ^{−3}	1.762
$\mu(\text{MoK}\alpha)$ / mm ^{−1}	1.142
<i>F</i> (000)	1112
Scan range, °	2.98 < θ < 25.51
Reciprocal lattice segments	<i>h</i> −14 → 14, <i>k</i> −15 → 15, <i>l</i> −17 → 16
Reflections collected	3860

Table I. Continued

Reflections independent [R_{int}]	2198 [0.078]
Data/restraints/parameters	3860/0/236
Goodness-of-fit on F^2	1.00
R_1 , wR_2 [$I > 2\sigma(I)$]	0.074, 0.183
R_1 , wR_2 (all data)	0.135, 0.209
Largest differences peak and hole ($e \text{ \AA}^{-3}$)	3.55 and -1.19

Crystallographic data for the structural analyses of **1** have been deposited with the Cambridge Crystallographic Data Centre, CCDC-658171. Copies of this information may be obtained free of charge from The Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (Fax: +44 1223-336033; E-mail: deposit@ccdc.cam.ac.uk; <http://www.ccdc.cam.ac.uk>).

Cytotoxicity assays

Preparation of the drug solutions. Stock solutions of the investigated ruthenium complexes were prepared in dimethyl sulfoxide (DMSO) at a concentration of 10 mM, filtered through a 0.22 μm Millipore filter before use and diluted with nutrient medium to various working concentrations. DMSO was used due to solubility problems. The nutrient medium was RPMI 1640 medium, without phenol red, supplemented with L-glutamine (3.0 mM), streptomycin (100 $\mu\text{g ml}^{-1}$), penicillin (100 IU ml^{-1}), 10 % fetal bovine serum (FBS) and 25 mM Hepes, was adjusted to pH 7.2 with bicarbonate solution. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was dissolved (5.0 mg ml^{-1}) in phosphate buffer saline, pH 7.2, and filtered through a 0.22 μm Millipore filter before use. All reagents were products of Sigma Chemicals.

Cell culture. Human cervix adenocarcinoma HeLa, malignant melanoma Fem-x and human breast carcinoma MDA-MB-361 and MDA-MB-453 cells were cultured as monolayers in the nutrient medium, while human myelogenous leukemia K562 cells were maintained as a suspension culture. The cells were grown at 37 °C in a 5.0 % CO_2 humidified air atmosphere. For the growth of MDA-MB-361 and MDA-MB-453 cells and all subsequent experiments, the complete medium was enriched with 1.11 g dm^{-3} glucose. Peripheral blood mononuclear cells (PBMC) were separated from whole heparinized blood of a healthy volunteer by Lymphoprep (Nycomed, Oslo, Norway) gradient centrifugation. The interface cells, washed three times with Haemaccel (aqueous solution supplemented with 145 mM Na^+ , 5.1 mM K^+ , 6.2 mM Ca^{2+} , 145 mM Cl^- and 35 g dm^{-3} gelatin polymers, pH 7.4) were counted and resuspended in nutrient medium.

Cell sensitivity analysis. HeLa (2,000 cells per well), Fem-x (2,000 cells per well), MDA-MB-361 (10,000 cells per well), and MDA-MB-453 cells (3,000 cells per well) were seeded into 96-well microtiter plates and 20 h later, after cell adherence, five different concentrations of the investigated compounds were added to the wells. The final concentrations were in the range from 12.5 to 200 μM . Only nutrient medium was added to the cells in the control wells. The investigated compounds were added to a suspension of leukemia K562 cells (3,000 cells per well) 2 h after cell seeding, in the same final concentrations as applied to the HeLa and Fem-x cells. All experiments were performed in triplicate. Nutrient medium with the corresponding concentrations of the compounds but void of cells was used as the blanks. PBMC were seeded (150,000 cells per well) into nutrient medium or into nutrient medium enriched with (5.0 $\mu\text{g ml}^{-1}$) phytohaemagglutinin (PHA, Wellcome Diagnostics, England) in 96-well microtiter plates and 2 h later the investigated compounds were added to the wells, in triplicate, at five final concentrations, except to the control wells where nutrient


medium only was added to the cells. Nutrient medium with the corresponding concentrations of the compounds but void of cells was used as the blanks.

Determination of target cell survival. Cell survival was determined by the MTT test according to the method of Mosmann³² modified by Ohno and Abe³³ and Drakulić *et al.*,³⁴ 72 h after drug addition. The concentration IC_{50} of the investigated compounds which diminished the survival of the target cells by 50 % was assessed from graphs of cell survival vs. concentration of the investigated compound.

RESULTS AND DISCUSSION

Synthesis of the complexes

The neutral $[(\eta^6$ -*p*-cymene)RuCl₂(K₃tsc)] (**2**) and cationic $[(\eta^6$ -*p*-cymene)-RuCl₂(CH₃NH(CH₂)₄NH)]PF₆ (**1**) organoruthenium complexes were obtained by reaction of K₃tsc and *N*-methylpiperazine, respectively, with $[(\eta^6$ -*p*-cymene)₂RuCl₂]₂ at ambient temperature (Scheme 1). Complex **1** is well soluble in water, ethanol (methanol) and DMSO, whereas complex **2** is less soluble in water and ethanol.



Scheme 1. Preparation of complexes **1** and **2**.

Thiosemicarbazones usually coordinate with a metal ion either in the neutral thione form or, after deprotonation, in the N,S ligand chelating mode. The diversity of coordination can be further increased by the introduction of an additional donor site into the thiosemicarbazone through the donor atom of carbonyl compounds.¹¹

X-ray diffraction study of **1**

The selected bond and angle parameters are listed in Table II. The molecule adopts the usual three-legged “piano-stool” arrangement generally found in

$[M(\eta^6\text{-arene})L_3]$ units (Fig. 1). Complex **1** is the first structurally characterized mononuclear complex of the $[\text{Ru}(\eta^6\text{-}p\text{-cymene})\text{Cl}_2L]$ type with the Ru atom bonded directly to a heterocyclic amine.

TABLE II. Selected bond lengths (Å) and angles (°) for complex **1**

Ru1–Cg ^a	1.674(5)	Ru1–Cl2	2.401(3)
Ru1–Cl1	2.420(2)	Ru1–N1	2.161(8)
Cg–Ru1–Cl1	127.15(16)	Cg–Ru1–Cl2	127.29(17)
Cg–Ru1–N1	135.0(2)	Cl1–Ru1–Cl2	87.63(9)
Cl1–Ru1–N1	82.2(2)	Cl2–Ru1–N1	80.6(2)

^aThe abbreviation Cg is the centroid of the η^6 -arene ligand




Fig. 1. ORTEP presentation of $[(\eta^6\text{-}p\text{-cymene})\text{RuCl}_2(\text{CH}_3\text{NH}(\text{CH}_2)_4\text{NH})]^+$ cation in crystals of **1**. Displacement ellipsoids are plotted at the 50 % probability level and H atoms are shown as small spheres of arbitrary radii.

The distance between the metal and the arene centroid, 1.674(5) Å is very similar to that observed in other ruthenium(II) complexes of the $[\text{Ru}(\eta^6\text{-}p\text{-cymene})\text{Cl}_2L]$ class (L/bond distance = dimethylamine/1.666; *sec*-butylamine/1.663–1.664; *p*-toluidine/1.637 Å).^{35–37} Similarly to the mentioned complexes, the angles between the "legs" of the stool are slightly less than 90°, due to steric hindrance of the arene ligand. The Ru–N distance (2.161(8) Å) is comparable with the same bond distance in $[\text{RuCl}_2(\eta^6\text{-}p\text{-cymene})(\text{NH}(\text{CH}_3)_2)]$ (2.165 Å), but it is significantly longer than those found in compounds of the same type,^{36,37} indicating a relatively weaker bond.

An interesting feature of this structure is the protonation of both N atoms of the *N*-methylpiperazine ring, probably originating from NH_4PF_6 .

Characterization of the complexes

The analytic and spectroscopic data of the synthesized complexes are as follows.

*[(η⁶-*p*-cymene)RuCl₂(CH₃NH(CH₂)₄NH)]PF₆ (1).* Anal. Calcd. for C₁₅H₂₇Cl₂N₂PF₆Ru: C, 32.62; H, 4.93; N, 5.07. Found: C, 32.82; H, 4.93; N, 4.94. IR (KBr, cm⁻¹): 3331–3435, 1630, 1467, 841. ¹H-NMR (199.97 MHz, DMSO-*d*₆, δ, ppm): 8.14 (1H, *s*, NH), 5.79, 5.51 (4H, *m*, η⁶-C₆H₄), 3.06 (4H, *t*, HN(CH₂)₂), 2.86 (4H, *m*, CH₃N(CH₂)₂), 2.30 (3H, *s*, NCH₃), 2.20 – 2.00 (4H, *m*, CH(CH₃)₂, η⁶-C₆H₄-CH₃), 1.20 (6H, *d*, CH(CH₃)₂). ¹³C-NMR (50 MHz, DMSO-*d*₆, δ, ppm): 106.60 (C-1), 100.31 (C-4), 86.58 (C-3,5), 85.73 (C-2,6), 51.46 (C-12,14), 45.60 (C-11,13), 43.14 (C-15), 30.18 (C-7), 21.70 (C-8,9), 18.07 (C-10). Electronic spectrum (H₂O) [λ_{\max} / nm (ϵ_{\max} / 10³ dm³ mol⁻¹ cm⁻¹)]: 386 (*sh*) (0.4), 306 (*sh*) (0.8), 255 (1.8).

*[(η⁶-*p*-cymene)RuCl₂(K₃tsc)] (2).* Anal. Calcd. for C₂₂H₂₆Cl₂N₃NaO₄S₂Ru: C, 40.31; H, 4.00; N, 6.41; S, 9.80. Found: C, 40.41; H, 4.12; N, 6.92; S, 10.35; IR (KBr, cm⁻¹): 3363–3437, 1682, 1619, 1224, 1031, 762. ¹H-NMR (199.97 MHz, DMSO-*d*₆, δ, ppm): 10.88 (1H, *s*, N⁴H), 9.70, 9.06 (2H, *s*, N³H₂), 8.52 (1H, *d*, PhH, *tsc*), 7.86 (1H, *d*, PhH, *tsc*), 7.57 (2H, *q*, PhH, *tsc*), 5.79, 6.28 (4H, *m*, η⁶-C₆H₄), 3.80 (1H, *d*, Ha, *tsc*), 2.87 (1H, *t*, Hb, *tsc*), 2.15 (4H, *m*, CH(CH₃)₂, η⁶-C₆H₄-CH₃), 1.51 (3H, *s*, CH₃, *tsc*), 1.23 (6H, *s*, CH(CH₃)₂). ¹³C-NMR (50 MHz, DMSO-*d*₆, δ, ppm): 194.94 (C-2), 179.21 (C-9), 144.70 (C-6), 138.19 (C-10), 133.05 (C-12), 132.96 (C-15), 129.17 (C-11), 126.42 (C-14), 124.88 (C-13), 107.98 (C-17), 102.32 (C-20), 85.67 (C-19,21), 83.60 (C-18,22), 65.50 (C-8), 56.25 (C-17), 35.27 (C-7), 30.52 (C-23), 22.26 (C-26), 21.33 (C-16), 18.76 (C-24), 17.98 (C-25). Electronic spectrum (H₂O/EtOH, 50/50) [λ_{\max} / nm (ϵ_{\max} / 10³ dm³ mol⁻¹ cm⁻¹)]: 275 (*sh*) (15.3), 244 (19.4), 223 (19.3).

NMR spectra

The ¹H-NMR spectra of both complexes displayed characteristic resonances which can be attributed to the coordination of *p*-cymene, as well as thiosemicarbazone, or *N*-methylpiperazine. In both complexes the signals corresponding to the phenyl ring of cymene moiety are at δ 5.79 and 5.51 (**1**) and at 6.26 and 5.79 (**2**) ppm. The signals which can be assigned to the two methyl groups of the isopropyl groups are at 1.20 (**1**) and 1.23 (**2**) ppm. The methyl group of the *p*-cymene moiety displays a signal at around δ 2.10 ppm for both complexes. The signals assigned to the CH group of the isopropyl group were centered at δ 2.10 (**1**) and 2.15 (**2**) ppm. Hydrogen resonances due to the CH₂ groups of the piperazine ring are located at 2.72–2.97 ppm, appearing as a triplet of triplets ((CH₂)₂NCH₃), whereas those attached to the NH part of the heterocycle appear as a triplet centered at 3.06 ppm. The resonance confirming the protonation of the piperazine nitrogen is located at 8.14 ppm. In complex **2**, the signals corresponding to the phenyl ring of the coordinated K₃tsc are at δ 7.57 (*q*), 7.86 (*d*) and

8.52 (*d*). Two resonances at 3.80 and 2.87 ppm were assigned to the two diastereotropic protons of the CH₂ group of the thiosemicarbazone moiety. A signal that can be assigned to the methyl group of thiosemicarbazone is at δ 1.51 (*s*) ppm. Two resonances at 9.06 and 9.70 ppm were assigned to the two protons of the N³H₂ chain, whereas the proton of the azomethine nitrogen appears at 11.88 ppm. The ¹³C-NMR spectrum of complex **1** shows upfield shifts (51.46 (C-2,6), 45.60 (C-3,5), 43.14 (C-7)) for the piperazine part of the molecule comparing to free piperazine (56.29 (C-2,6), 46.75 (C-3,5) and 45.67 (C-7)), due to coordination *via* the unsubstituted N-4 nitrogen. In the spectrum of complex **2**, a slight upfield shift of C-2 was observed as a consequence of *S*-metallation, while no remarkable shifts of the other carbon atoms were observed.

Infrared spectra

The spectrum of the free ligand, K₃tsc, was compared with those of the complexes to confirm its coordination to metal ion. The ν (CS) vibrations suffer a negative shift from 1278 (**L**) to 1232 cm⁻¹ (**2**). Also, the ν (CN) vibration of the C²–N⁴ bond is slightly shifted to lower frequencies due to the partial multiplicity of this bond after coordination. The peaks at 1690 cm⁻¹ in the spectrum of the free ligand due to ν (C=O) vibrations and at 1639 cm⁻¹ due to ν (CN) vibrations of C⁶–N⁵ remained unchanged in the complex, confirming the non-coordination of oxygen and the azomethine nitrogen to the metal ion.

This study showed that in complex **2**, K₃tsc acts as a neutral monodentate ligand, which is coordinated to the metal ion *via* the sulfur atom.

UV/Vis spectra

The complexes exhibit intense absorption in the visible region which can be ascribed to high intensity metal-to-ligand charge transfer bands which interfere with the expected d–d transitions, as is observed in low-spin d⁶ ruthenium(II) complexes.³⁸ In general, complexes **1** and **2** exhibit two well resolved bands. The bands at higher wavelengths can be ascribed to a Ru(4d π) \rightarrow π^* (NH) MLCT transition, whereas the bands at lower wavelengths are attributable to intraligand transitions or a combination of MLCT bands and intraligand transitions.

Cytotoxicity assays

The *in vitro* cytotoxicity of complexes **1** and **2** was determined by an MTT-based assay. The complexes were tested for cytotoxic activity on tumor cell lines: human adenocarcinoma HeLa, human myelogenous leukemia K562, human malignant melanoma Fem-x, human breast carcinoma MDA-MB-361 and MDA-MB-453 cells and on normal immunocompetent cells, *i.e.*, on human peripheral blood mononuclear PBMC cells non-stimulated and stimulated for proliferation with phytohaemagglutinin (PHA). The data are given in Table III and Fig. 2.

TABLE III. IC_{50} (μ M) for 72 h of action of the investigated compounds on various tumor cells and on non-stimulated PBMC and PBMC stimulated with PHA, determined by the MTT test

Tumor cell	Compound	
	1	2
HeLa	>200	62.50 \pm 3.54
K562	>200	71.26 \pm 4.22
Fem-x	>200	152.10 \pm 5.18
MDA-MB-361	>200	101.84 \pm 6.54
MDA-MB-453	>200	62.46 \pm 5.98
PBMC-PHA	Not detected	61.10 \pm 1.12
PBMC+PHA	Not detected	40.38 \pm 1.12




Fig. 2. Survival of tumor cells, determined by the MTT test after 72 h of continuous action of the applied concentrations of the investigated complexes 1 (—●—) and 2 (—■—), as a function of the concentration of the tested compounds.

Complex **1** exerted low activity against all the selected cell lines ($IC_{50} > 200 \mu\text{M}$, Table III and Fig. 2) as determined by the MTT test. This result is consistent with the characteristics of ruthenium compounds which are generally less cytotoxic than platinum compounds. One of two ruthenium complexes that is under clinical investigations, *trans*-[HInd][RuCl₄(Ind)₂] (Ind = indazole; KP1019) is only moderately cytotoxic to cancer cells,³⁹ whereas the other complex, *trans*-[HIm]-[RuCl₄(DMSO)(Im)] (Im = imidazole; NAMI-A) is relatively non-toxic to primary cancer cells, but exhibits antimetastatic activity.⁴⁰

Complex **2** showed low to moderate activity with $IC_{50} = 152.10 \mu\text{M}$ for Fem-x and $IC_{50} = 101.84 \mu\text{M}$ for the slowly proliferating MDA-MB-361 cells. Against HeLa, K562 and the rapidly proliferating MDA-MB-453 cell lines, compound **2** exerted a moderate dose dependent antiproliferative action, with IC_{50} values of 62.50, 71.26 and 62.46 μM , respectively. Complex **2** was more active against the normal control PBMC, with $IC_{50} = 61.10 \mu\text{M}$ for non-stimulated resting PBMC and $IC_{50} = 40.38 \mu\text{M}$ for PBMC stimulated by PHA. Results from this work are in accordance with many publications which deal with antitumor activity of metal complexes of thiosemicarbazones^{13,14,22} and of antileukemia potency of thiosemicarbazones.^{41,42} In addition, this compound acted toxically, especially to PBMC which were stimulated for proliferation. This indicates that the mentioned complex might also have a capability for the suppression of autoimmune diseases. Further investigations in this direction need to be performed.

CONCLUSIONS

Two new organoruthenium complexes were synthesized and characterized. The results from this work showed that the ruthenium complex containing vitamin K₃-thiosemicarbazone as the organic part exerted its maximal cytotoxic activity against immunocompetent cells stimulated for proliferation. The higher activity of this complex compared with the complex containing *N*-methylpiperazine is probably related with the presence of vitamin K₃-thiosemicarbazone, itself active. In addition, the obtained data indicate that complex **2** could be further studied regarding its promising action for the control not only of malignant diseases, but also for the control of autoimmune diseases.

Acknowledgement. This work was supported by the Ministry of Science of the Republic of Serbia, Grant Nos. 142010 and 145006. The authors would like to thank Ms. Jelena Lazić and Mr. Aleksandar Savić for their help in the experimental part of this work.

ИЗВОД

СИНТЕЗА, СТРУКТУРНА КАРАКТЕРИЗАЦИЈА И ЦИТОТОКСИЧНА АКТИВНОСТ ДВА НОВА ОРГАНОРУТЕНИЈУМ(II) КОМПЛЕКСА

САЊА ГРГУРИЋ-ШИПКА¹, МОНАМЕД АЛ. АРБИ М. АЛСХТЕВТ¹, ДЕЈАН ЈЕРЕМИЋ¹, ГОРАН Н. КАЛУЂЕРОВИЋ², SANTIAGO GÓMEZ-RUIZ³, ЖЕЉКО ЖИЖАК⁴, ЗОРИЦА ЈУРАНИЋ⁴ и ТИБОР Ј. САБО¹

¹Хемијски факултет, Универзитет у Београду, Студентски брџ 12–16, 11000 Београд, ²Институт за хемију, технологију и металургију – Центар за хемију, Њежићева 12, 11000 Београд, ³Departamento de Química Inorgánica y Analítica, E. S. C. E. T., Universidad Rey Juan Carlos, 28933 Móstoles, Madrid, Spain и ⁴Институт за онкологију и радиологију, 11000 Београд

Синтетисана су два нова *p*-цимен-рутенијум(II) комплекса који садрже као додатне лиганде *N*-метилпиперазин ($[(\eta^6\text{-}p\text{-cimen})\text{RuCl}_2(\text{CH}_3\text{NH}(\text{CH}_2)_4\text{NH})]\text{PF}_6$, комплекс **1**) и витамин К₃-тиосемикарбазон ($[(\eta^6\text{-}p\text{-cimen})\text{RuCl}_2(\text{K}_3\text{tsc})]$, комплекс **2**). Оба нова комплекса добијена су полазећи од $[(\eta^6\text{-}p\text{-cimen})_2\text{RuCl}_2]_2$ комплекса и одговарајућег лиганда. Комплекси су окарактерисани елементалном анализом, ИЦ, електронско-апсорпционом и НМР спектроскопијом. Рендгено-структурна анализа комплекса **1** показала је „piano-stool“ геометрију. У зависности од присутног лиганда дискутована је разлика у цитотоксичној активности ова два добијена комплекса.

(Примљено 27. децембра 2007, ревидирано 4. марта 2008)

REFERENCES

1. Y. K. Yan, M. Melchart, A. Habtemariam, P. J. Sadler, *Chem. Commun.* (2005) 4764
2. M. Melchart, P. J. Sadler, in *Bioorganometallics: Biomolecules, Labeling, Medicine*, G. Jaouen, Ed., Wiley-VCH, Weinheim, (2006), p. 39
3. C. S. Allardyce, A. Dorcier, C. Scolaro, P. J. Dyson, *Appl. Organomet. Chem.* **19** (2005) 1
4. C. N. Kato, A. Shinohara, N. Moriya, K. Nomiya, *Catal. Commun.* **7** (2006) 413
5. P. Pelagatti, A. Bacchi, F. Calbani, M. Carcelli, L. Elviri, C. Pelizzi, D. Rogolino, *J. Organomet. Chem.* **690** (2005) 4602
6. R. E. Aird, J. Cummings, A. A. Ritchie, M. Muir, R. E. Morris, H. Chen, P. J. Sadler, D. I. Jodrell, *Br. J. Cancer* **86** (2002) 1652
7. R. E. Morris, R. E. Aird, P. del S. Murdoch, H. M. Chen, J. Cummings, N. D. Hughes, S. Parsons, A. Parkin, G. Boyd, D. I. Jodrell, P. J. Sadler, *J. Med. Chem.* **44** (2001) 3616
8. V. Siguret, *Hematologie* **12** (2006) 389
9. S. A. Akman, R. Dietrich, R. Chlebowsky, P. Limberg, J. B. Block, *Cancer Res.* **45** (1995) 5257
10. D. X. West, S. B. Padhye, P. B. Sonawane, *Struct. Bonding* **76** (1991) 1
11. J. S. Casas, M. S. García-Tasende, J. Sordo, *Coord. Chem. Rev.* **209** (2000) 197
12. D. C. Greenbaum, Z. Mackey, E. Hensell, P. Doyle, J. Gut, C. R. Caffrey, J. Lehrman, P. J. Rosenthal, J. H. McKerrow, K. Chibale, *J. Med. Chem.* **47** (2004) 3212
13. L. Feun, M. Modiano, K. Lee, J. Mao, A. Marini, N. Savaraj, P. Plezia, B. Almassian, E. Colacino, J. Fischer, S. MacDonald, *Cancer Chemother. Pharmacol.* **50** (2002) 223
14. J. Murren, M. Modiano, C. Clairmont, P. Lambert, N. Savaraj, T. Doyle, M. Sznol, *Clin. Cancer Res.* **9** (2003) 4092
15. E. C. Moore, A. C. Sartorelli, in *Inhibitors of Ribonucleoside Diphosphate Reductase Activity*, J. G. Cory, A. H. Cory, Eds., Pergamon Press, Oxford, 1989, pp. 203
16. H. L. Elford, M. Freese, E. Passamani, H. P. Morris, *J. Biol. Chem.* **245** (1970) 5228
17. Q. Li, H. Tang, Y. Li, M. Wang, L. Wang, C. Xia, *J. Inorg. Biochem.* **78** (2000) 167
18. H. A. Tang, L. F. Wang, L. D. Yang, *Trans. Met. Chem.* **28** (2003) 395

19. J. S. Casas, E. E. Castellano, M. D. Couce, J. Ellena, A. Sánchez. J. Sordo, C. Taboada, *J. Inorg. Biochem.* **100** (2006) 1858
20. U. K. Mazumder, M. Gupta, S. S. Karki, S. Bhattacharya, S. Rathinasamy, S. Thangavel, *Chem. Pharm. Bull.* **52** (2004) 178
21. F. Bregant, S. Pacor, S. Ghosh, S. K. Chattopadhyah, G. Sava, *Anticancer Res.* **13** (1993) 1011
22. S. Grgurić-Šipka, C. R. Kowol, S. M. Valiahdi, R. Eichinger, M. A. Jakupec, A. Roller, S. Shova, V. B. Arion, B. K. Keppler, *Eur. J. Inorg. Chem.* **18** (2007) 2870
23. A. Habtemariam, M. Melchart, R. Fernández, S. Parsons, I. D. H. Oswald, A. Parkin, F. P. A. Fabbiani, J. E. Davidson, A. Dawson, R. E. Aird, D. I. Jodrell, P. J. Sadler, *J. Med. Chem.* **49** (2006) 6858
24. S. M. Guichard, R. Else, E. Reid, B. Zeitlin, R. Aird, M. Muir, M. Dodds, H. Fiebig, P. J. Sadler, D. I. Jodrell, *Biochem. Pharm.* **71** (2006) 408
25. C. Sclaro, A. Bergamo, L. Brescacin, R. Delfino, M. Cocchietto, G. Lauerencyz, T. J. Geldbach, G. Sava, P. J. Dyson, *J. Med. Chem.* **48** (2005) 4161
26. B. Serli, E. Zangrando, T. Gianferrara, C. Sclaro, P. J. Dyson, A. Bergamo, E. Alessio, *Eur. J. Inorg. Chem.* **17** (2005) 3423
27. H. Chen, J. A. Parkinson, R. E. Morris, P. J. Sadler, *J. Am. Chem. Soc.* **125** (2003) 173
28. S. B. Jensen, S. J. Rodger, M. D. Spicer, *J. Organomet. Chem.* **556** (1998) 151
29. SCALE3 ABSPACK, Empirical absorption correction, CrysAlis – Software package, Oxford Diffraction Ltd., 2006
30. G. M. Sheldrick, SHELXS-97, Program for Crystal Structure Solution, Gottingen, 1997
31. G. M. Sheldrick, SHELXL-97, Program for the Refinement of Crystal Structures, Gottingen, 1997
32. T. Mosmann, *J. Immunol. Meth.* **65** (1983) 55
33. M. Ohno, T. J. Abe, *J. Immunol. Meth.* **145** (1991) 199
34. B. J. Drakulić, Z. D. Juranić, T. P. Stanojković, I. O. Juranić, *J. Med. Chem.* **48** (2005) 5600
35. D. B. Dell'Amico, F. Calderazzo, L. Labella, F. Marchetti, E. Sbrana, *J. Organomet. Chem.* **651** (2002) 52
36. P. Pertici, E. Pitzalis, G. U. Barretta, F. Marchetti, P. Salvadori, *Gazz. Chim. Ital.* **125** (1995) 27
37. M. J. Begley, S. Harrison, A. H. Wright, *Acta Crystallogr.: C* **47** (1991) 318
38. D. Mishra, S. Naskar, M. G. B. Drew, S. Kumar Chattopadhyah, *Inorg. Chim. Acta* **359** (2006) 585
39. A. Galeano, M. R. Berger, B. K. Keppler, *Arzneim.-Forsch./Drug. Res.* **42** (1992) 821
40. G. Sava, R. Gagliardi, A. Bergamo, E. Alessio, G. Mestroni, *Anticancer Res.* **19** (1999) 969
41. I. Gojo, M. L. Tidwell, J. Greer, N. Takebe, K. Seiter, M. F. Pochron, B. Johnson, M. Sznol, J. E. Karp, *Leuk. Res.* **31** (2007) 1165
42. K. W. L. Yee, J. Cortes, A. Ferrajoli, G. Garcia-Manero, S. Verstovsek, W. Wierda, D. Thomas, S. Faderl, I. King, S. M. O'Brien, S. Jeha, M. Andreeff, A. Cahill, M. Sznol, F. J. Giles, *Leuk. Res.* **30** (2006) 813.